The Potential Antitumor Effects of Capsaicin

2014 ◽  
pp. 181-208 ◽  
Author(s):  
Inés Díaz-Laviada ◽  
Nieves Rodríguez-Henche
Keyword(s):  
Antitumor Effects ◽  
Potential Antitumor

scholarly journals Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Sara Baldassari ◽  
Agnese Solari ◽  
Guendalina Zuccari ◽  
Giuliana Drava ◽  
Sara Pastorino ◽  
...  
Keyword(s):  
Slow Release ◽  
Antitumor Effects ◽  
Potential Antitumor

scholarly journals Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib

RSC Advances ◽  
2021 ◽  
Vol 11 (59) ◽  
pp. 37462-37471
Author(s):  
Lin Tang ◽  
Tingting Chen ◽  
Hongpeng Yang ◽  
Xiaoxue Wen ◽  
Yunbo Sun ◽  
...  
Keyword(s):  
Antitumor Agents ◽  
Antitumor Effects ◽  
Sulfone Derivatives ◽  
Potential Antitumor

In this work, a series of novel benzyl naphthyl sulfoxides/sulfones derived from Rigosertib were designed and synthesized as potential antitumor agents.

scholarly journals Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

2020 ◽  
Vol 8 (1) ◽  
pp. e000590 ◽  
Author(s):  
Jacob L Goldberg ◽  
Fariba Navid ◽  
Jacqueline A Hank ◽  
Amy K Erbe ◽  
Victor Santana ◽  
...  
Keyword(s):  
Phase I Study ◽  
Antitumor Effects ◽  
Clinical Correlates ◽  
Patients With Cancer ◽  
Humanized Monoclonal Antibody ◽  
Human Igg1 ◽  
Clinical Associations ◽  
Mouse Igg2a ◽  
Igg1 Isotype ◽  
Potential Antitumor

PurposePatients with cancer receiving tumor-reactive humanized monoclonal antibody (mAb) therapy can develop a human antihuman antibody (HAHA) response against the therapeutic mAb. We evaluated for HAHA in patients with neuroblastoma treated in a phase I study of humanized anti-GD2 mAb (immunoglobulin (Ig)G1 isotype), hu14.18K322A (NCT00743496). The pretreatment sera (collected prior to mAb treatment) from 9 of 38 patients contained antitherapeutic antibodies, even though they had no prior mAb exposure. We sought to characterize these pre-existing antitherapeutic antibodies (PATA).Experimental designThe PATA+ pretreatment samples were characterized via ELISA; clinical associations with PATA status were evaluated.ResultsPretreatment sera from eight of nine PATA+ patients also bound rituximab and demonstrated preferential ELISA reactivity against the Fc portions of hu14.18K322A and rituximab as compared with the Fab portions of these mAbs. These PATA+ sera also recognized dinutuximab (human IgG1 isotype) and mouse IgG2a isotype mAbs, but not a mouse IgG1 isotype or the fully human panitumumab (IgG2 isotype) mAb. Of the 38 treated patients, only 4 patients (all in the PATA+ cohort) demonstrated no disease progression for>2.5 years without receiving further therapy (p=0.002).ConclusionsThis study demonstrates an association between clinical outcome and the presence of PATA against determinant(s) on the Fc component of the therapeutic mAb, suggesting that the PATA may be playing a role in augmenting mAb-based antitumor effects. Further analyses for the presence of PATA in a larger cohort of patients with relapsed neuroblastoma, analyses of their clinical correlates, identification of their immunological targets, and potential antitumor mechanisms are warranted.

scholarly journals Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities

2021 ◽  
Vol 43 (2) ◽  
pp. 558-589
Author(s):  
Wamidh H. Talib ◽  
Asma Ismail Mahmod ◽  
Ayah Kamal ◽  
Hasan M. Rashid ◽  
Aya M. D. Alashqar ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Ketogenic Diet ◽  
Cell Metabolism ◽  
New Combination ◽  
Antitumor Effects ◽  
Low Carbohydrate ◽  
Therapeutic Mechanisms ◽  
Cancer Cell Metabolism ◽  
Therapy Studies ◽  
Potential Antitumor

Although cancer is still one of the most significant global challenges facing public health, the world still lacks complementary approaches that would significantly enhance the efficacy of standard anticancer therapies. One of the essential strategies during cancer treatment is following a healthy diet program. The ketogenic diet (KD) has recently emerged as a metabolic therapy in cancer treatment, targeting cancer cell metabolism rather than a conventional dietary approach. The ketogenic diet (KD), a high-fat and very-low-carbohydrate with adequate amounts of protein, has shown antitumor effects by reducing energy supplies to cells. This low energy supply inhibits tumor growth, explaining the ketogenic diet’s therapeutic mechanisms in cancer treatment. This review highlights the crucial mechanisms that explain the ketogenic diet’s potential antitumor effects, which probably produces an unfavorable metabolic environment for cancer cells and can be used as a promising adjuvant in cancer therapy. Studies discussed in this review provide a solid background for researchers and physicians to design new combination therapies based on KD and conventional therapies.

RENISUS Plants and Their Potential Antitumor Effects in Clinical Trials and Registered Patents

2020 ◽  
pp. 1-28
Author(s):  
Diorge Jônatas Marmitt ◽  
Shanna Bitencourt ◽  
Gustavo Rodrigo da Silva ◽  
Claudete Rempel ◽  
Márcia Inês Goettert
Keyword(s):  
Clinical Trials ◽  
Antitumor Effects ◽  
Potential Antitumor

scholarly journals A valproátterápia túlélésre gyakorolt hatása gliomás betegekben

2021 ◽  
Vol 162 (24) ◽  
pp. 960-967
Author(s):  
Tamás Mezei ◽  
Dávid Mészáros ◽  
Péter Pollner ◽  
Attila Bagó ◽  
Imre Fedorcsák ◽  
...  
Keyword(s):  
Antiepileptic Drugs ◽  
Inhibitory Effects ◽  
First Line ◽  
Antitumor Effects ◽  
Antiepileptic Agent ◽  
Kaplan Meier ◽  
Epileptic Patients ◽  
Survival Prolongation ◽  
Supratentorial Glioma ◽  
Potential Antitumor

Összefoglaló. Bevezetés: A gliomák, ezen belül a glioblastoma kezelése továbbra is megoldatlan onkológiai problémát jelent. A szekunder szimptómás epilepsziabetegség megjelenése pozitív prognosztikai faktornak tekinthető a korai diagnosztizálás és az antiepileptikumok potenciális tumorellenes hatásának köszönhetően. A valproát túlélést hosszabbító hatása már több mint 20 éve az alap- és klinikai kutatások tárgyát képezi. Napjainkban ismert citotoxikus, proapoptotikus, antiangiogenetikus és hiszton-deacetiláz-gátló hatásmechanizmusa. Célkitűzés: Kutatásunk célja a valproát túlélést hosszabbító hatásának vizsgálata egy hazai gliomás betegcsoportban. Módszer: Egycentrumos, retrospektív klinikai vizsgálatot végeztünk. A vizsgálatba 122 felnőtt beteget vontunk be, akiknél 2000 januárja és 2018 januárja között supratentorialis glioma miatt műtét történt, és rohamtevékenység miatt antiepileptikumot (valproát, levetiracetám, karbamazepin) szedtek. Egyúttal gyógyszert nem szedő kontrollcsoportot is kialakítottunk. A populációt vizsgálati és kontrollcsoportokra osztottuk 28 : 52 arányban. Leíró statisztikai, Kaplan–Meier- és log-rank analízist végeztünk. Eredmények: A vizsgált szövettani kategóriák túlélési analízise az irodalmi adatokkal megegyező értékeket mutatott. A progressziómentes (PFS: p = 0,031) és a teljes (OS: p = 0,027) túlélés tekintetében is szignifikáns eltérés mutatkozott a különböző antiepileptikumot szedő betegcsoportok között, amely még kifejezettebbé vált a valproátot és az egyéb antiepileptikumot szedő betegek túlélési idejének összehasonlítása során (PFS: p = 0,006; OS: p = 0,015). Következtetés: Vizsgálatunkban a valproát betegeink PFS- és OS-idejének meghosszabbodását eredményezte. Az irodalmi adatok és kutatásunk alapján megfontolandónak tartjuk a valproát első vonalban történő alkalmazását onkoterápiában részesülő, epilepsziás, agyi gliomás betegekben. Orv Hetil. 2021; 162(24): 960–967. Summary. Introduction: Gliomas still prove to be a serious oncological problem. The presence of epilepsy may present a favorable prognosis due to early diagnosis and the potential antitumor effects of antiepileptic drugs. The survival prolongation effect of valproate has been studied for more than 20 years, nowadays its proapoptotic, anti-angiogenetic, cytotoxic and histone deacetylase inhibitory effects are well known. Objective: Our goal was to investigate the survival-enhancing effects of valproate in a Hungarian patient cohort of primary brain tumors. Method: A single-center based retrospective clinical trial was designed. In our study, we included 122 patients harboring supratentorial glioma who underwent surgery and experienced seizures between 2000 January and 2018 January. The patients were grouped by the antiepileptic therapies and survival analysis was performed. Results: The Kaplan–Meier curves of the histological categories showed the survival values consistent with the data of the literature. The progression-free (PFS: p = 0.031) and the overall (OS: p = 0.027) survival of the antiepileptic drug categories were significantly different. It was performed by comparing the valproate group and the population formed by the other groups which also showed a significant increase in the survival values (PFS: p = 0.006; OS: p = 0.015). Conclusion: Our results show that valproate increases the PFS and OS period of glioma patients in comparison to other antiepileptic drugs. Our data suggest that the use of valproic acid should be considered as a first-line antiepileptic agent in certain well-selected epileptic patients with glioma as a supplement to the oncotherapy. Orv Hetil. 2021; 162(24): 960–967.

Sign in / Sign up

Export Citation Format

Share Document